Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Present at the Emergencies in Medicine Conference on Advancing Concussion Treatment

Core Insights - Oragenics, Inc. is participating in the Emergencies in Medicine Conference to present advancements in concussion treatments, specifically focusing on their novel intranasal neurosteroid, ONP-002 [1][2][3] Company Overview - Oragenics is a development-stage biotechnology company that specializes in nasal delivery of pharmaceutical medications targeting neurological conditions and infectious diseases, including treatments for mild traumatic brain injury (concussion) and Niemann Pick Disease Type C [4] Product Development - The presentation by Dr. James Kelly will highlight the "Trigger-to-Treat" program for concussion, emphasizing ONP-002's role in acute treatment and its integration with BRAINBox Solutions' diagnostic platform for improved concussion detection and patient stratification [2][3] Clinical Advancements - The "Trigger-to-Treat" paradigm aims to enhance acute concussion care by enabling early identification of high-risk patients and timely interventions, potentially accelerating recovery and reducing long-term neurological complications [3] Conference Details - The Emergencies in Medicine Conference serves as a platform for healthcare professionals and researchers to discuss innovations in emergency and trauma care, with a significant focus on concussion treatment [3]